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Abstract
Objective To compare cancer control in anterior compared to posterior prostate cancer lesions treated with a focal HIFU 
therapy approach.
Materials and methods In a prospectively maintained national database, 598 patients underwent focal HIFU  (Sonablate®500) 
(March/2007–November/2016). Follow-up occurred with 3-monthly clinic visits and PSA testing in the first year with 
PSA, every 6–12 months with mpMRI with biopsy for MRI-suspicion of recurrence. Treatment failure was any secondary 
treatment (ADT/chemotherapy, cryotherapy, EBRT, RRP, or re-HIFU), tumour recurrence with Gleason ≥ 3 + 4 on prostate 
biopsy without further treatment or metastases/prostate cancer-related mortality. Cases with anterior cancer were compared 
to those with posterior disease.
Results 267 patients were analysed following eligibility criteria. 45 had an anterior focal-HIFU and 222 had a posterior 
focal-HIFU. Median age was 64 years and 66 years, respectively, with similar PSA level of 7.5 ng/ml and 6.92 ng/ml. 84% 
and 82%, respectively, had Gleason 3 + 4, 16% in both groups had Gleason 4 + 3, 0% and 2% had Gleason 4 + 4. Prostate 
volume was similar (33 ml vs. 36 ml, p = 0.315); median number of positive cores in biopsies was different in anterior and 
posterior tumours (7 vs. 5, p = 0.009), while medium cancer core length, and maximal cancer percentage of core were com-
parable. 17/45 (37.8%) anterior focal-HIFU patients compared to 45/222 (20.3%) posterior focal-HIFU patients required 
further treatment (p = 0.019).
Conclusion Treating anterior prostate cancer lesions with focal HIFU may be less effective compared to posterior tumours.
Keywords Prostate cancer · Focal therapy · High intensity focused ultrasound · Biochemical failure
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Introduction
Since high-intensity focused ultrasound (HIFU) was first 
started for the treatment of prostate cancer [1], treatment 
parameters have been refined from ablating the whole 
prostate gland to hemi-gland ablation, quadrant ablation 
and so-called ultra-focal ablation of cancerous areas [2]. 
Less than whole-gland approaches seem to confer reassur-
ing medium-term cancer control with reduced side-effects 
and complications [3], provided patients are staged and 
selected appropriately [4].
The energy source for HIFU is usually placed in the 
patient’s rectum, with ultrasound waves having to traverse 
a number of tissue planes. There can be loss of energy 
by passing multiple tissue planes and large volumes of 
tissue between source and prostate tumour. There has 
been some concern as to whether HIFU is able to confer 
similar cancer control rates for treating anterior prostate 
tumours. Indeed, the reported local intraprostatic swell-
ing and prostate shift during the treatment [5] may have 
a higher impact on anterior parts of the prostate, with the 
anterior border of the lesion drifting away from the energy. 
We aimed to compare cancer control in anterior compared 
to posterior prostate cancer lesions treated with a focal 
HIFU therapy approach.
Methods
The UCLH Joint Research Office granted institutional 
review board exemption. Between March/2007 and 
November/2016, 598 consecutive patients underwent 
primary focal HIFU (focal lesion ablation or quadrant or 
hemiablation) for non-metastatic prostate cancer using 
the Sonablate®500 device (Sonacare Inc., USA) within 
nine centres. Hemiablations were excluded from this 
analysis. Prior to consensus articles which streamlined 
eligibility criteria for focal therapy in prostate cancer, it 
was not known nor agreed which cases may benefit most. 
As a result, focal HIFU treatment was initially offered to 
patients diagnosed with non-metastatic prostate cancer 
with Gleason 6 through 9, stage T1c-T3bN0M0 and PSA 
of ≤ 20 ng/ml. Gleason 6 required a minimum of 3 mm 
of disease. Over the last 5 years, the UK Focal Therapy 
Users Group predominantly treats men with stage T1c-
T2cN0M0, Gleason 7 and PSA ≤ 20  ng/ml. For this 
analysis, only patients with Gleason ≥ 7 were included 
since positive recurrence was defined as Gleason ≥ 7 as 
described below. Furthermore, for all cases analysed pros-
tate size in the group with tumour located in posterior area 
of the gland was limited to the maximum of prostate size 
of the comparator group. 267 patients were eligible for 
analysis in this study as they had more than 3 months fol-
low-up and information on tumour location. Disease was 
localised using mpMRI, combined with targeted and sys-
tematic biopsies, or transperineal mapping biopsies. Cases 
were separated into anterior or posterior groups according 
to tumour location in mpMRI where each prostate gland 
was arithmetically divided in half in anterior–posterior 
dimensions.
Treatments included in this analysis were delivered in a 
focal lesion ablation or quadrant fashion depending on the 
gland volume as well as tumour volume and location. Index 
lesion ablation alone was conducted in patients with multifo-
cal disease provided untreated areas harboured no more than 
3 mm of Gleason 6 on systematic or template mapping biop-
sies. All men were advised to undergo 3–6 monthly serum 
PSA testing. An mpMRI was routinely performed regardless 
of PSA changes at 1 year and approximately 1–2 yearly there-
after. Two rises in PSA after the nadir level was achieved, 
without predefining the level of rise, was investigated with a 
prostate biopsy, or mpMRI followed by biopsy if the mpMRI 
was suspicious. We have previously reported on the high 
negative predictive value of mpMRI in the post-focal HIFU 
setting for clinically significant prostate cancer [6]. Clinically 
significant cancer on biopsy of untreated areas was defined as 
‘out-of-field’ progression.
Treatment failure was defined by any secondary treatment 
(ADT/chemotherapy, cryotherapy, EBRT, RRP, or re-HIFU), 
metastasis from prostate cancer without further treatment, 
tumour recurrence with Gleason score ≥ 7 proved by prostate 
biopsy without further treatment, or death from prostate can-
cer, respectively.
Statistical analysis
Variables with skewed distribution are reported as median 
(interquartile ranges, IQR). Categorical variables are reported 
as absolute numbers with percentages. Significance levels for 
median values were calculated with Mood’s Median Test, and 
treatment results with Fisher’s Exact Binomial Test. Multi-
variate analysis was performed with logit models using the 
following factors: age, PSA level pre-treatment, and prostate 
volume were used as continuous parameters, whereas tumour 
location (anterior vs. posterior), clinical T stage (< cT3 vs. 
≥ cT3), and Gleason score (< 4 + 3 vs. ≥ 4 + 3) were catego-
rised. Analyses were performed using the R language envi-
ronment for statistical computing. p < 0.05 was considered as 
statistically significant.
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Results
Baseline demographics
From a total of 598 focal primary HIFU cases, and applying 
eligibility criteria 267 patients were analysed, divided into a 
group of 45 cases with an anterior, and a group of 222 cases 
with a posterior located prostate tumour treatment (Table 1). 
Since prostate volume in posterior tumour group was limited 
to the maximum of prostate volume in anterior tumour group 
there was no significant difference. In the anterior group, no 
Gleason 4 + 4 was treated while in the posterior group 2% 
of cases were Gleason 4 + 4. The number of positive cores 
in biopsies pre-treatment was significantly higher in ante-
rior tumour group compared to posterior tumour location 
(median 7 vs. 5, p = 0.009).
Treatment outcome
The two groups showed statistically significant different fail-
ure rates. In anteriorly located tumours failure occurred in 
17/45 cases (37.8%), whereas in posteriorly located tumours 
45/222 cases (20.3%) had a treatment failure (p = 0.019). 
There were no differences in time to treatment failure or 
follow-up without failure (Table 2). In multivariate analysis 
using logit models anterior tumour location and ≥ cT3 stage 
resulted as a significant predictor for treatment outcome 
(Table 3).
Discussion
In summary, we have shown that failure following focal 
HIFU is related to the position of the cancer in the ante-
rior–posterior plane. Prior to discussing the clinical impli-
cations of our study, there are some limitations that require 
mentioning. First, it is a retrospective analysis of a national 
database with heterogeneity in case-mix. Second, there was 
not an underlying protocol, so we could not mandate biopsy 
in all men, particularly if the PSA was stable. Third, we 
lack long term evaluation of metastases and mortality and 
therefore used a composite endpoint [7]. Last, we were not 
able to evaluate whether apical versus mid-gland or base 
locations had impact on the failure rates.
Although focal treatment modalities have demonstrated 
their ability in treating prostate cancer [8], there are some 
technical limitations in HIFU. The probe used in our study 
(Sonablate500) has two pre-defined focal energy points 
at 4 cm and 3 cm lengths, there is an inherent limitation 
for glands which are large or have an AP length of much 
greater than 3.5 cm [9, 10]. What we have shown is that 
Table 1  Baseline demographics
N number, IQR inter quartile range, ADT androgen deprivation therapy, MRI magnetic resonance imaging, ml millilitres, MCCL maximum can-
cer core length, cm centimetre
Determinant Anterior tumour Posterior tumour p value
Median/mean/N IQR/% Median/mean/N IQR/%
Age at treatment (in years), median, (IQR) 64 59–68 66 60–71 0.531
ADT pre treatment, N, (%) 5 11% 24 11% 0.970
PSA pre treatment (in ng/ml), median, (IQR) 7.53 5.22–10.77 6.92 5.05–9.64 0.496
Prostate volume (MRI, in ml), mean, (range) 33 28–40 36 28–47 0.315
Biopsy results pre treatment, median, (IQR)
 No. positive cores 7 3–13 5 4–9 0.009
 MCCL (in mm) 6.5 5–8.75 6 4–8 0.597
 Max. cancer percentage of core (%) 50 40–76 60 39–75 0.507
Gleason score pre treatment, median 3 + 4 3 + 4
 3 + 4 38 84% 181 82% 0.832
 4 + 3 7 16% 36 16% 1.000
 4 + 4 0 0% 5 2% 0.593
T-stage pre treatment, median, N, (%) T2 T2
 T1c 5 11% 10 4% 0.145
 T2a 3 7% 15 7% 1.000
 T2b 27 60% 117 53% 0.415
 T2c 6 13% 50 22% 0.228
 T3a 4 9% 28 13% 0.619
 T3b 0 0% 2 1% 1.000
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even when the probe can reach the lesion there is a rel-
evant difference in successful treating of cancers local-
ised more anteriorly compared to those closer to the rectal 
probe. There still seems to be an issue with ablative effi-
cacy likely related to loss of energy as the pulse traverses 
multiple planes of tissue. With the high resolution and 
precision of a mpMRI for outlining prostate cancer board-
ers an accurate planning instrument is available [11]. The 
distance between rectal wall and the most anterior tumour 
border can be defined precisely, and unsuitable cases for 
HIFU with a tumour location beyond the maximal focal 
point have to be excluded. In our practice, we now use 
interstitial needle based ablative therapies [12, 13].
When planning a HIFU treatment for anterior prostate 
tumours one should bear in mind the intraprostatic changes, 
which are produced by heating energy through ablation. 
There is an intraprostatic swelling phenomenon that occurs 
as well as shifting of the prostate, demonstrated for whole-
gland HIFU treatments [5], and even when a smaller area is 
treated focally, a certain shift of the targeted area away from 
the focal point has to be kept in mind.
Unlike in other focal ablative technologies—like cryo-
therapy, irreversible electroporation or laser approaches—
where ablative energy can be delivered directly into a desired 
intraprostatic area, the HIFU energy source distributes its 
energy from an extra-prostatic point-source. Therefore, 
there is a higher loss of ablative energy in anterior located 
tumours, when more tissue needs to be crossed to reach the 
region of interest. For anterior areas, there is always more 
energy absorbed by posterior prostatic parenchyma than for 
posterior areas [14]. Whilst overall rates of cancer control 
are acceptable in the medium term in men with clinically 
significant prostate cancer [15], in this retrospective analysis 
a significantly higher recurrence rate for anterior located 
prostate cancers compared to posterior tumours is demon-
strated. When comparing the underlying baseline demo-
graphics, there is a significant higher number of positive 
cores in the anterior tumour group. This difference must be 
a result of different number of total biopsy cores taken, since 
there was no protocol used how many cores have to be taken 
from suspicious lesions.
Conclusion
Treating anterior prostate cancer lesions with focal HIFU 
may be less effective compared to posterior tumours.
Author contributions PH, HUA, SG and NM were responsible for data 
collection, analysis of the data. HUA and PH were responsible for 
production of the first draft. PH and HUA completed the data analysis. 
All authors were involved in data collection, manuscript preparation/
drafting and approval of the final draft. HUA had full access to all of 
the data in the study and takes responsibility for the integrity of the data 
Table 2  Treatment outcomes
N number, IQR inter quartile range, mpMRI multiparametric MRI, mth month, ADT androgen deprivation therapy
Determinant Anterior tumour Posterior tumour p value
Median/mean/N IQR/range/% Median/
mean/N
IQR/range/%
Total patients, N 45 222
Recurrences in treated area, N, (%) 17 37.8% 45 20.3% 0.019
Proof of recurrence by
 Biopsy, N, (% of recurrences) 8 47% 22 49% 0.930
 mpMRI, N, (% of recurrences) 9 53% 23 51% 1.074
Time to recurrence (mth), mean, (range) 28.5 22–41 21 18–36 0.274
Follow-up without recurrence (mth), mean, (range) 29 15.5–46 19 11–41 0.030
Secondary treatment modality
 Secondary HIFU, N, (% of recurrences) 9 53% 39 87%
 Cryoablation, N, (% of recurrences) 6 35% 0 0%
 Radical prostatectomy, N, (% of recurrences) 1 6% 5 11%
 Radiotherapy, N, (% of recurrences) 1 6% 1 2%
Table 3  Multivariate analysis: predictors for treatment failure
OR odds ratio, IQR inter quartile range
Determinant OR IQR p value
Age at treatment 0.973 0.93–1.01 0.192
PSA pre-treatment 1.054 0.98–1.13 0.152
Prostate volume 0.992 0.97–1.02 0.526
Anterior tumour location 0.304 0.14–0.64 0.002
Clinical T stage ≥ cT3 3.831 2.03–7.39 < 0.001
Gleason score ≥ 4 + 3 1.754 0.80–3.75 0.152
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